UAE Antiepileptic Drugs Market Size Analysis, Growth Trends & Forecast to 2034

UAE Antiepileptic Drugs Market Overview 

The UAE antiepileptic drugs market is projected to expand from USD 0.11 billion in 2026 to USD 0.15 billion by 2034, registering a CAGR of 4.7% during 2026–2034. The UAE antiepileptic drugs market is fueled by the increasing need for epilepsy treatment, rising knowledge about neurological conditions, and the availability of numerous anti-seizure drugs. The market comprises several drug types such as sodium channel blockers, GABA agonists, and broad-spectrum antiepileptic drugs in both branded and generic forms. The demand for antiepileptic drugs is fueled by the requirement for long-term treatment, better seizure control, and tolerability of medicines, along with the rise in the adoption of next-generation drugs that present new opportunities for pharma companies. Market competition is marked by the presence of MNCs and regional firms providing innovative and generic drugs.

UAE Antiepileptic Drugs Market Growth Drivers

Increasing Burden of Epilepsy and Neurological Disorders

There has been an increasing burden of neurological diseases in the UAE. The rise in the cases of neurological illnesses has led to the increased requirement for effective diagnosis, treatment and management of the illness that has contributed to an increase in the demand for antiepileptic medicines. As per the National Multiple Sclerosis Society’s review report on the incidence of neurological diseases in the UAE released in November 2023, the lack of epidemiological data indicates the need for better understanding and research of the requirements of the neurological health care sector of the country. This, in turn, leads to increased focus on neurological health infrastructure facilities and treatments. As far as the antiepileptic medicines market is concerned, such trends contribute to the growth in demand for antiepileptic medicines.

Growing Adoption of Advanced Antiseizure Medications

The increasing use of modern antiepileptic drugs is facilitating growth in terms of new treatment possibilities in the UAE antiepileptic drugs market, especially for adult patients with needs for better control of seizures. According to the Hikma Pharmaceuticals press release in July 2026, the pharmaceutical company introduced XCOPRI (cenobamate) tablets in the UAE market, being the first product based on cenobamate that was launched in the country for the treatment of partial-onset seizures in adult epileptic patients. The launch of the drug, which is licensed exclusively by SK Biopharmaceuticals, adds possibilities for new-generation treatments that can be utilized alone or together with other antiepileptic drugs. Such availability of advanced treatments allows for expanding therapeutic options for physicians, especially when the patients' seizures cannot be adequately controlled using existing drugs.

UAE Antiepileptic Drugs Market Restraint

Medication Side Effects and Challenges Associated with Long-Term Treatment Adherence

The prolonged administration of antiepileptics can be hindered by side effects due to the medication, complications in the regimen, and difficulties in maintaining consistent adherence to it. Dizziness, fatigue, lethargy, cognitive side effects, and mood disturbances are common side effects of antiepileptic medications, and their negative impact on patients' lifestyle and well-being may result in alteration of doses, discontinuation of therapy, and switching to another type of drug. Sometimes, patients need to resort to combination therapy for proper seizure control, and in that case, the process becomes even more complicated due to the potential occurrence of drug interactions.

UAE Antiepileptic Drugs Market Opportunities

Expansion of Generic Antiepileptic Drug Portfolios and Affordable Treatment Options

The increased range of generics in the portfolio of antiepileptics offers an opportunity for pharmaceutical companies in the UAE to meet the rising demands of affordable and accessible epilepsy therapies. Increased access to generic products in commonly prescribed drugs such as levetiracetam, valproate, lamotrigine, and carbamazepine can offer cost-effective substitutes to branded therapies while ensuring continuous use of medication over time. It is possible to increase their market share by developing products in a range of doses and formulations, which include tablets, extended-release tablets, and oral suspensions. This business opportunity is more applicable for regional pharmaceuticals looking to establish themselves through the development of generic medicines.

Growing Commercial Potential for New-Generation Antiepileptic Therapies

There is great business potential for next-generation antiepileptics, which can help drug companies establish themselves in the UAE through innovative antiepileptic treatments that are geared towards providing better control of seizures and higher tolerance of the medicine. There is increasing emphasis on the importance of treating people suffering from inadequate seizures; thus, there is room for the development of new molecules with novel ways of action, pharmacological benefits, and limited disadvantages compared to traditional treatments. Companies can take advantage of this business opportunity by developing more advanced anticonvulsants, getting additional approvals, and partnering up with healthcare organizations. The introduction of new drugs can also help companies diversify their portfolios and introduce premium-priced branded drugs in the UAE antiepileptic drug market.

UAE Antiepileptic Drugs Market Scope

UAE Antiepileptic Drugs Market Report Segmentation Analysis

The Sodium Channel Modulators Segment Is Expected to Dominate the UAE Antiepileptic Drugs Market During the Forecast Period

The sodium channel modulators segment is anticipated to lead the UAE antiepileptic drugs market over the forecast period owing to their extensive use in treating various forms of epileptic seizures and being a part of standard treatment protocols. Medicines like carbamazepine, lamotrigine, phenytoin and lacosamide function by modulating the activity of the neuronal sodium channels, thereby balancing electrical activities in the brain and preventing abnormal seizures. Their availability in both branded and generic versions, along with clinical familiarity among neurologists and their utility in the long-term treatment of epilepsy, will ensure continued prescription demand. The development of new drugs that modulate sodium channels is further adding to the treatment options available for the management of seizures.

Oral Segment Is Expected to Dominate the UAE Antiepileptic Drugs Market During the Forecast Period

The oral segment is estimated to be dominant in the UAE Antiepileptic Drugs Market over the forecast period owing to the high adoption of oral drugs in managing seizures. Orally administered drugs, such as tablets, capsules, and oral solutions, are easy to administer, allow for easily adjustable dosing, and are convenient to take at outpatient clinics. Availability of older and next-generation antiepileptic drugs in both immediate-release and extended-release formulations will contribute to the growth of the segment. Oral drugs allow for home treatment, thereby increasing the availability of treatment options. Generic drugs make treatment more affordable for the long run.

The Tablet and Capsules Segment Is Expected to Dominate the UAE Antiepileptic Drugs Market During the Forecast Period

The tablets & capsules segment is anticipated to be the dominant segment in the UAE antiepileptic drugs market during the forecast period, owing to their wide prescription for regular treatment of epilepsy. These drug forms can be administered conveniently, are easy to dose, have good storage capacity, and are ideal for patients who need continuous dosing to remain free from seizures. The wide availability of antiepileptic drugs that are widely prescribed, such as levetiracetam, valproate, carbamazepine, and lamotrigine in the form of tablets and capsules, will help boost the segment demand. Extended-release formulations will create opportunities for simplifying dosing schedules of patients on long-term therapy.

The Hospital Pharmacies Segment Is Expected to Dominate the UAE Antiepileptic Drugs Market During the Forecast Period

The hospital pharmacies segment is anticipated to dominate the UAE antiepileptic drugs market during the forecast period owing to the role played by hospitals in the diagnosis and initiation of treatment for epilepsy patients. Epilepsy patients who are experiencing new-onset seizures, recurrence, or uncontrolled epilepsy are likely to need consultation and alteration of their medication, which will increase prescriptions and dispensation of medicines through hospital pharmacies. Neurologists, diagnoses, and specialized healthcare services available at hospitals further add to this route of distribution. Hospital pharmacies are known to have a wide variety of branded and generic antiepileptic drugs, including next-generation drugs, available through them.

The following segments are part of an in-depth analysis of the UAE Antiepileptic Drugs Market:

UAE Antiepileptic Drugs Market Competition Landscape Analysis

Competition within the UAE Antiepileptic Drugs Market arises from the rivalry between multinational companies that produce well-known and new anticonvulsants against regional companies that manufacture generics. The major firms in this market are UCB Pharma, Sanofi, GSK, Novartis, Julphar and Neopharma. They compete through product portfolio development, pricing, regulations and healthcare alliances. New drugs like Hikma Pharmaceuticals' XCOPRI (cenobamate) highlight the increasing emphasis on innovation within the market. Competition within the market is mainly shaped by product differentiation, generics, cost, physician preference and availability.

UAE Antiepileptic Drugs Market Recent Developments News:

• In 2026, Immedica announced that the UAE had granted marketing authorization for ZTALMY (ganaxolone), indicated for seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and above. The approval expands access to a specialized treatment for rare, difficult-to-control epilepsy and highlights growing opportunities for targeted antiseizure therapies in the UAE market.

• In July 2026, Hikma Pharmaceuticals launched XCOPRI (cenobamate) in the UAE for treating partial-onset seizures in adults with epilepsy. Introduced under an exclusive licensing agreement with SK Biopharmaceuticals, the once-daily therapy expands access to newer-generation antiseizure medications and strengthens the availability of treatment options for patients with inadequately controlled seizures.  

The UAE Antiepileptic Drugs Market is dominated by a few large companies, such as

• UCB Pharma

• Sanofi

• GlaxoSmithKline (GSK)

• Novartis

• Gulf Pharmaceutical Industries (Julphar)

• Pfizer

• Neopharma

• Nexgen Pharma

• Lifepharma

• Torrent Pharmaceuticals

• SPIMACO

• Laboratorios Cinfa

• Jamjoom Pharmaceuticals

• Camber Pharmaceuticals

• Hikma Pharmaceuticals

• Taha Pharma

• Syri Limited

• United Pharmaceutical Manufacturing Company

• Tabuk Pharmaceutical Manufacturing Company

• Farmoz

• Other Prominent Players